P G Rose

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. ncbi Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
    P G Rose
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Int J Gynecol Cancer 15:18-22. 2005
  2. ncbi A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
  3. ncbi Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
  4. ncbi Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity
    Peter G Rose
    Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA
    Gynecol Oncol 89:429-33. 2003
  5. ncbi Stage IIB-IVA cancer of the cervix
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Cancer J 9:404-14. 2003
  6. ncbi Combined-modality therapy of locally advanced cervical cancer
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Clin Oncol 21:211s-217s. 2003
  7. ncbi Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy
    P G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio, 44106, USA
    Gynecol Oncol 82:17-21. 2001
  8. ncbi Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages
    P G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 82:323-8. 2001
  9. ncbi Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study
    J P Curtin
    Department of Obstetrics and Gynecology, Cornell University Medical College, NY, USA
    J Clin Oncol 19:1275-8. 2001
  10. ncbi Combined radiation therapy and chemotherapy for carcinoma of the cervix
    P G Rose
    Division of Gynecologic Oncology, and the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Cancer J 7:86-94. 2001

Collaborators

Detail Information

Publications59

  1. ncbi Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
    P G Rose
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Int J Gynecol Cancer 15:18-22. 2005
    ....
  2. ncbi A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
    ..The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients...
  3. ncbi Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
    ..To evaluate prolonged oral etoposide in nonsquamous cell carcinoma of the cervix, the current phase II trial was conducted...
  4. ncbi Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity
    Peter G Rose
    Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA
    Gynecol Oncol 89:429-33. 2003
    ....
  5. ncbi Stage IIB-IVA cancer of the cervix
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Cancer J 9:404-14. 2003
    ..However, these improvements, currently practiced in developed countries, must be implemented in underdeveloped countries which have the greatest burden of this disease...
  6. ncbi Combined-modality therapy of locally advanced cervical cancer
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Clin Oncol 21:211s-217s. 2003
    ..The potential role of biologic agents in combination with chemoradiotherapy also needs to be examined in locally advanced cervical cancer...
  7. ncbi Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy
    P G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio, 44106, USA
    Gynecol Oncol 82:17-21. 2001
    ..CONCLUSIONS: These results suggest that despite technical modifications the sensitivity of PET before second-look laparotomy for small-volume persistent disease is low...
  8. ncbi Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages
    P G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 82:323-8. 2001
    ....
  9. ncbi Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study
    J P Curtin
    Department of Obstetrics and Gynecology, Cornell University Medical College, NY, USA
    J Clin Oncol 19:1275-8. 2001
    ..The overall response rate was 31%. The primary and dose-limiting toxicity was neutropenia. CONCLUSION: The response rate to paclitaxel exceeds the rates reported using other single agents in nonsquamous carcinoma of the cervix...
  10. ncbi Combined radiation therapy and chemotherapy for carcinoma of the cervix
    P G Rose
    Division of Gynecologic Oncology, and the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Cancer J 7:86-94. 2001
    ..This review summarizes studies of sequential and concurrent combinations of chemotherapy and radiation therapy for the treatment of cervical cancer, as well as the recent controversies related to this treatment...
  11. ncbi Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study
    P G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospital of Cleveland, OH 44106, USA
    Gynecol Oncol 62:100-2. 1996
    ..8%. Grade 3 peripheral neurotoxicity occurred in 3.4%. There were no objective responses, demonstrating that this agent is useful in previously treated squamous cell carcinoma of the cervix...
  12. ncbi Malignant melanoma of the vulva: an extension of cutaneous melanoma?
    K M Moxley
    Division of Gynecologic Oncology, University of Oklahoma HSC, Oklahoma City, OK, USA
    Gynecol Oncol 122:612-7. 2011
    ....
  13. ncbi Significance of cytologically normal endometrial cells in cervical smears from postmenopausal women
    V R Sarode
    Department of Pathology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA
    Acta Cytol 45:153-6. 2001
    ..Women who were not on HRT had a higher incidence of endometrial pathology...
  14. ncbi Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer
    M Rodriguez
    University Hospital of Cleveland, Case Western Reserve University, Ireland Comprehensive Cancer Center, USA
    Am J Obstet Gynecol 185:370-4. 2001
    ..Long-term survival of patients treated with radical trachelectomy for early invasive cervical cancer are yet to be determined...
  15. ncbi Locally advanced cervical cancer
    P G Rose
    Division of Gynecologic Oncology, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Curr Opin Obstet Gynecol 13:65-70. 2001
    ..The use of concurrent chemotherapy and radiation therapy has resulted in a significant increase in patient survival. Our understanding of cervical tumor biology has the potential for further improvements...
  16. ncbi Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006?
    P G Rose
    Division of Gynecologic Oncology, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA
    Ann Oncol 17:x224-9. 2006
  17. ncbi Chemoradiotherapy for cervical cancer
    P G Rose
    Division of Gynecologic Oncology, University Hospitals of Cleveland and The Ireland Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
    Eur J Cancer 38:270-8. 2002
    ..e. concurrently with radiation therapy), as the new standard of therapy for cervical cancer...
  18. ncbi Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report
    William C McBee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 105:244-7. 2007
    ..Mixed yolk sac tumors of the ovary are biologically aggressive even in early stage disease...
  19. ncbi Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
    Bradley J Monk
    Department of Ob Gyn, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, and Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    Gynecol Oncol 105:427-33. 2007
    ..To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation...
  20. ncbi Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
    ....
  21. ncbi Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group
    Paul A DiSilvestro
    Program in Womens Oncology, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, and Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City 73190, USA
    Gynecol Oncol 103:1038-42. 2006
    ..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer...
  22. ncbi Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
    ..A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum number of days) of sequential oral topotecan and oral etoposide...
  23. ncbi Docetaxel in ovarian cancer
    Pedro F Escobar
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, A-81, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Expert Opin Pharmacother 6:2719-26. 2005
    ..This article reviews the rationale and indications for the use of docetaxel in ovarian cancer...
  24. ncbi Role of surgery in ovarian carcinoma
    Amanda Nickles Fader
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2873-83. 2007
    ..The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed...
  25. ncbi Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    Fiona Simpkins
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A81, Cleveland, OH, 44195, USA
    Gynecol Oncol 107:118-23. 2007
    ..Since the initial report of this complication, we have limited bevacizumab treatment to patients without: 1) clinical symptoms of bowel obstruction 2) evidence of rectosigmoid involvement on pelvic exam 3) bowel involvement on CT scan...
  26. ncbi Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2804-10. 2007
    ....
  27. ncbi A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation Case Western Reserve University, Cleveland, OH 44195, USA
    Am J Clin Oncol 31:476-80. 2008
    ....
  28. ncbi Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
    Mark A Morgan
    Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Gynecol Oncol 110:329-35. 2008
    ....
  29. ncbi Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 109:329-34. 2008
    ..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
  30. ncbi Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 109:323-8. 2008
    ..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
  31. ncbi Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    J Clin Oncol 26:83-9. 2008
    ..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
  32. ncbi Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73104, USA
    Gynecol Oncol 107:398-403. 2007
    ..Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers. We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison...
  33. ncbi Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007
    ..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
  34. ncbi A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 107:274-9. 2007
    ..To determine the maximum tolerated dose (MTD) of gemcitabine followed by cisplatin that can be administered weekly during pelvic radiation therapy in patients with locally advanced cervical cancer...
  35. ncbi A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma
    Peter G Rose
    MetroHealth Medical Center, Cleveland, Ohio 44195, USA
    Gynecol Oncol 99:714-9. 2005
    ..This phase I/II trial combined weekly topotecan, which is less myelosuppressive than the standard 5-day regimen, with carboplatin in patients with potentially platinum-sensitive relapsed ovarian or peritoneal carcinoma (PS-OVCa/PCa)...
  36. ncbi Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Lari Wenzel
    Center for Health Policy Research, Division of General Internal Medicine, College of Medicine, University of California, Irvine, USA
    J Clin Oncol 23:5605-12. 2005
    ..Interestingly, there were fewer complaints of neurotoxicity at 6 months among patients who did versus did not undergo interval secondary cytoreduction...
  37. ncbi A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Gynecol Oncol 85:136-9. 2002
    ..There are no immediate plans to study this combination further...
  38. ncbi Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma
    Peter G Rose
    Case Western Reserve University and Ireland Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Ohio 44106, USA
    Gynecol Oncol 88:17-21. 2003
    ..CONCLUSION: The combination of gemcitabine and cisplatin is active in patients who are platinum resistant. Additionally, activity is demonstrated even in patients who have previously been resistant to gemcitabine...
  39. ncbi Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  40. ncbi Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland, OH 44109, USA
    Gynecol Oncol 91:423-5. 2003
    ..Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy...
  41. ncbi Chemoradiation for locally advanced cervical cancer: does it help?
    Peter G Rose
    J Clin Oncol 20:891-3. 2002
  42. ncbi Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer
    Peter G Rose
    MetroHealth Medical Center, Cancer Care Pavilion, Room 2017, 2500 MetroHealth Dr, Cleveland, OH 44109, USA
    Semin Oncol Nurs 19:25-35. 2003
    ..IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses play a valuable role in ovarian cancer care by proactively meeting patient information needs...
  43. ncbi Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
    Katherine Y Look
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:644-7. 2004
    ..5%. CONCLUSION: Gemcitabine demonstrates activity in patients with persistent or recurrent uterine LMS and should be considered in multiagent regimens treating this patient population...
  44. ncbi Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer
    Rachel A Dubay
    Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109-1998, USA
    Gynecol Oncol 94:121-4. 2004
    ..The efficacy of carboplatin, compared to cisplatin, as a radiation sensitizer can only be determined in a randomized clinical trial...
  45. ncbi Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  46. ncbi Secondary surgical cytoreduction for advanced ovarian carcinoma
    Peter G Rose
    Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, USA
    N Engl J Med 351:2489-97. 2004
    ....
  47. ncbi A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 96:296-300. 2005
    ..We studied weekly paclitaxel and 3-week carboplatin in potentially platinum-sensitive recurrent ovarian and peritoneal carcinoma...
  48. ncbi Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer
    Peter G Rose
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A 81, Cleveland, Ohio 44195, USA
    Oncologist 10:205-14. 2005
    ....
  49. ncbi Management of locally advanced cervical cancer
    Luis A Rojas-Espaillat
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Oncol 17:485-92. 2005
    ....
  50. ncbi Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology
    Robert Kim
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, OH 44195, USA
    Surg Oncol Clin N Am 14:267-88. 2005
  51. ncbi Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 22:343-9. 2004
    ..Two patients experienced grade 4 hematologic adverse effects. CONCLUSION: Irofulven administered at the dose and schedule used in this trial was minimally active and resulted in significant toxicity...
  52. ncbi Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review
    Peter G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Ohio, USA
    Expert Opin Pharmacother 3:1245-9. 2002
    ..In conclusion, cisplatin-based chemoradiation regimens increased mean survival at an acceptable cost per life-year gained in both the in-patient and out-patient settings...
  53. ncbi Arterial thrombosis in a gynecologic oncology patient: evaluation and management
    Andrew E Green
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 87:228-30. 2002
    ..Presentation, evaluation, and treatment varied considerably in all previous reports of arterial thrombosis associated with any malignancy...
  54. ncbi Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study
    Michael A Gold
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Cancer 112:1954-63. 2008
    ....
  55. ncbi Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value
    Peter G Rose
    Obstet Gynecol 101:1022; author reply 1023. 2003
  56. ncbi Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study
    Paula M Fracasso
    Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Gynecol Oncol 103:523-6. 2006
    ..A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy...
  57. ncbi The flower looks as good as its bud
    Peter G Rose
    Am J Obstet Gynecol 197:443-4. 2007
  58. ncbi Pegylated liposomal doxorubicin in ovarian cancer
    Andrew E Green
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Nanomedicine 1:229-39. 2006
    ....
  59. ncbi Innovations in the treatment of invasive cervical cancer
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
    Cancer 98:2052-63. 2003
    ..Research advances in both diagnosis and treatment are expected to improve therapy and outcomes...